In addition, PPARγ agonist inhibitors have been shown to suppress cell growth and induce apoptosis of prostate cancer cells by both PPARγ-dependent (genomic) and - independent (non-genomic) signalling pathways. Here, PPARG is linked to prostate carcinoma.